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ABSTRACT 
Ever more emerging combined treatments exploiting synergistic effects of drug combinations 
demand for smart, responsive co-delivery carriers to reveal their full potential. In this study, a 
multifunctional stimuli-responsive amphiphilic peptide was designed and synthesized to self-
assemble into nanoparticles capable of co-bearing and -releasing hydrophobic drugs and 
antisense oligonucleotides (AONs) for combined therapies. The rational design was based on a 
hydrophobic L-tryptophan-D-leucine repeating unit derived from a truncated sequence of 
gramicidin A (gT), to entrap hydrophobic cargo, which is combined with a hydrophilic moiety of 
histidines to provide electrostatic affinity to nucleotides. Stimuli-responsiveness was 
implemented by linking the hydrophobic and hydrophilic sequence through an artificial amino 
acid bearing a disulfide functional group (H3SSgT). Stimuli-responsive peptides self-assembled 
Page 1 of 35
ACS Paragon Plus Environment
Biomacromolecules
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 2
in spherical nanoparticles in sizes (100-200 nm) generally considered as preferable for drug 
delivery applications. Responsive peptide nanoparticles revealed notable nucleotide condensing 
abilities while maintaining the ability to load hydrophobic cargo. The disulfide cleavage site 
introduced in the peptide sequence induced responsiveness to physiological concentrations of 
reducing agent, serving to release the incorporated molecules. Furthermore, the peptide 
nanoparticles, singly loaded or co-loaded with boron-dipyrromethene (BODIPY) and/or AONs, 
were efficiently uptaken by cells. Such amphiphilic peptides that led to non-cytotoxic, reduction-
responsive nanoparticles capable of co-delivering hydrophobic and nucleic acid payloads 
simultaneously provide potential towards combined treatment strategies to exploit synergistic 
effects. 
 
INTRODUCTION 
Combined treatments are gaining increasing impact in medicine to exploit synergistic effects 
of therapeutics but also to overcome multi drug resistance (MDR) in cancer therapies
1
. This 
creates a tremendous demand for sophisticated carriers systems capable of co-delivering 
therapeutics simultaneously for higher efficacy. For this purpose not only combinations of small 
drugs are beneficial but also drug/gene combinations are of high interest, especially in the case of 
P-glycoprotein (P-gp) mediated MDR.
1
 Nanotechnology provides a vast array of opportunities 
and promise in the rational design of multifunctional drug delivery systems. Nanocarriers can be 
designed for the delivery of therapeutics: protecting them from being metabolized
2, 3
, enhancing 
bioavailability, lowering off-target effects, and decreasing the necessary drug dose by increasing 
accumulation at the diseased site.
4
 Of particular interest for P-gp mediated MDR is the co-
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delivery of drugs and nucleic acids in a single nanocarrier system. Promising results were 
obtained by AON-mediated down-regulation of the over expressed P-gp, responsible for drug 
efflux, in combination with small molecule anti-cancer drugs.
5, 6
 For incorporation of payloads 
two main strategies are followed, where nucleic acids or drugs are either synthetically conjugated 
to the carrier or non-covalently condensed or entrapped.
2, 7
 Covalent strategies involve the 
linkage of polymers, proteins, peptides, and inorganic nanoparticles to nucleic acids or drugs,
8
 
while non-covalent condensation is achieved via electrostatic interaction, hydrogen bonding, and 
hydrophobic interactions. Non-covalent nanocarriers for oligonucleotide delivery are usually 
able to cross cell membranes and deliver the cargo better than conjugated ones, but are in general 
more difficult to control
7, 9
. Current strategies for co-delivery of small molecule drugs and 
nucleic acids rely on lipids
10, 11
, polymers
12, 13
, and conjugates
14, 15
, which form structures able to 
entrap small drugs as well as to non-covalently condense DNA or RNA. Further improvement of 
efficacy can be achieved by utilizing physiological microenvironments at pathological sites such 
as pH
16-19
, temperature
20
, and redox potential
21, 22
 as release triggers. Responsive polymeric 
systems and conjugates for co-delivery were developed recently, bearing moieties sensitive to 
physiological triggers such as pH
23-26
 or redox potential
27-30
. 
Emerging peptide based self-assembled nanostructures in the field of nanomedicine are 
particularly interesting because they are considered to be inherently biocompatible and 
biodegradable
31-33
. Specific inter- and intramolecular interactions between amino acids such as 
electrostatic interactions, hydrogen-bonding, hydrophobic interactions, and π-π-stacking can be 
implemented to obtain highly ordered and defined assemblies. The bottom up rational design is 
based on selecting amino acids with the desired properties in order to create novel amphiphilic 
peptides able to self-assemble into defined architectures (micelles
34, 35
, vesicles
31, 36, 37
, fibers
38
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and other nanoparticles
39, 40
). Furthermore, the combination of distinct functionalities, such as 
responsiveness, can be implemented within one molecule enabling the development of peptides 
self-assembling into well-defined and multifunctional nanoparticles, which is a tremendous 
advantage due to simplicity and applicability for biomedical applications
41-43
. Reported peptidic 
carriers for delivering a single drug comprise polyplexes
44-46
, hydrogels
47
, and micelles
42, 43, 48-50
. 
There are only a few peptidic co-delivery systems described to date capable of delivering nucleic 
acids and small molecule drugs simultaneously
42, 49, 50
. Recent reports describe peptides, 
consisting of a polyhistidine-polylysine hydrophilic peptide sequence coupled with a 
hydrophobic sequence comprised of alanine, phenylalanine and/or leucine, which show 
synergistic cytotoxic effects when delivering p53 plasmid in combination with doxorubicin 
(Dox) or paclitaxel (PTX)
49, 50
. Another report describes a slow release (20-30 hours) of Dox 
from a polyhistidine-TAT conjugate at pH 5 compared to neutral pH accompanied by synergistic 
effects when co-delivered with p53 plasmid
42
. However, further improvement for stimuli 
responsiveness is essential to enhance a rapid delivery and/or release of co-loaded payloads. 
Recently, we reported amphiphilic peptides based on a hydrophobic region (region 3, Figure 1) 
consisting of a truncated gramicidin A (gT) sequence
51, 52
, combined with a short hydrophilic 
sequence which can form micelles
34, 35
, fibers
34
, vesicles
53
 and peptide nanoparticles
40
. 
Combination of gT part with acetylated lysines (AcX3gT) leads to their assembly into peptide 
nanoparticles. They showed embedding of hydrophobic and hydrophilic payloads and can form 
ordered gold nanoparticle superstructures
39
. The multi compartment micellar (MCM) inner 
structure of the nanoparticles
54
 provides similar volume fractions for hydrophilic and 
hydrophobic payload but lacking sites for nucleic acid condensation and stimuli-triggered release 
mechanisms.  
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Here we aim for a straightforward rational design of new peptide nanoparticles that enhance 
the properties of the AcX3gT nanoparticles to favor co-delivery and rapid release of small 
molecule drugs and nucleic acids simultaneously by reduction-responsiveness. The new peptides 
are separated into three key structural features: the hydrophilic part (region 1), linker unit (region 
2), and hydrophobic part (region 3) (Figure 1). The hydrophilic moiety was redesigned from the 
previous peptide AcX3gT by implementing nucleotide condensing sites, based on oligo histidine, 
known to promote these interactions.
55
 By introducing oligo histidine the slight surface charge is 
in addition intended to prevent aggregation, which limited AcX3gT potential use,
40
 when loaded 
with hydrophobic molecules. Moreover, using oligo histidine as hydrophilic part preserves 
secondary aggregation to nanoparticles due to a pKa of 6.0 in contrast to earlier reported non-
acetylated K3gT, bearing lysines with a pKa of 10.7, which are forming micelles.
35
  
Increasing the number of aromatic side chains is expected to support molecules incorporation as 
already reported for AcX3gT. The nanoparticles were also expected to be smaller, thus more 
suitable for biomedical applications due to higher water solubility compared to AcX3gT.
35, 54
 
The stimuli-responsiveness to cellular redox potential was integrated to the sequence by using an 
artificial disulfide amino acid (region 2, Figure 1). By adding this linker in-between the 
hydrophilic and hydrophobic sequences, we favor a higher release upon external stimuli, which 
was previously not available when designed only with peptide bonds. Therefore, in the structure 
of this new peptide, only the gramicidin inspired seven amino acid repeating unit gT remained 
from the earlier reported peptide AcX3gT in order to maintain the previously observed self-
assembly into nanoparticles that are capable of entrapping hydrophobic payloads. 
Characterization revealed that the three functional units enabled assembly of spherical peptide 
nanoparticles that were reduction sensitive (H3SSgT) and capable of loading desired model drug 
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(boron-dipyrromethene (BODIPY)) and nucleic acid (antisense oligonucleotide (AON)) payloads 
simultaneously. We selected BODIPY as model molecule with the appropriate hydrophobicity 
and molecular weight, whilst the hydrophilic DoxHCl served only to demonstrate the ability of 
the peptide nanoparticles to encapsulate hydrophilic molecules as well. Fluorescence correlation 
spectroscopy (FCS) analysis was used to evaluate whether the reduction responsive particles 
were able to rapidly release all payloads in a reducing environment. A final analysis in HeLa 
cells was performed to show that the reduction-sensitive H3SSgT peptide nanoparticles are 
uptaken and the cargo retain its functionality. Although stimuli-responsive co-delivery 
architectures have been developed for polymer, lipid, and peptide-conjugate self-assemblies our 
strategy has the advantage of providing purely peptidic and biodegradable nanoparticles for 
efficient co-delivery and release of oligonucleotides and drugs simultaneously upon reduction. 
 
 
 
Figure 1. Schematic representation of nanoparticle assembly. Designed amphiphilic peptide 
consists of three regions: hydrophilic (region 1), reducible linker (region 2), and hydrophobic 
(region 3). Amphiphilic peptides assemble in a first step into micelles, incorporating drug in the 
hydrophobic part and nucleotides along their hydrophilic part. Further self-assembly leads to 
spherical nanoparticles, potentially multicompartment micelles.
54
 Adapted from Gunkel-Grabole 
et al.
56
 – Reproduced by permission of The Royal Society of Chemistry. 
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MATERIALS AND METHODS 
Materials. All reagents and materials were of the highest commercially available grade and 
used without further purification, unless otherwise mentioned. Rink Amide AM resin (0.71 
mmol/g), 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HCTU) and Fmoc-Trp(Boc)-OH were obtained from IRIS Biotech GmbH. Boc-Cystamine-Suc-
OH was purchased from IRIS Biotech GmbH and converted into Fmoc-Cystamine-Suc-OH 
amino acid as described previously
57
. All other amino acids were purchased from Novabiochem. 
Dimethylformamide (DMF) was obtained from J.T. Baker, ethanol (96 %) F15 and 
dichloromethane from Brenntag Schweizerhall AG, diisopropylethylamine (DIPEA) was ordered 
from VWR and acetonitrile (ACN) from Fisher Scientific. BODIPY 630/650 was purchased 
from Invitrogen. Atto550-labeled, 22-mer Oligonucleotide (Atto550-ODN) (5' TAA CAG GAT 
TAG CAG AGC GAG G3') was obtained from Microsynth. Doxorubicin hydrochloride 
(DoxHCl) (98%) was purchased from Beijing Zhongshuo Pharmaceutical Technology 
Development Co., Ltd. (China). DMEM, fetal bovine serum, Opti-MEM, and Penn/strep were 
obtained from Gibco. CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was 
purchased from Promega. FCCS standard double labeled DNA (488/633) was obtained from 
IBA (Göttingen, Germany). All other chemicals and reagents were ordered from Sigma-Aldrich. 
Free amines in DMF were eliminated by aluminum oxide prior to usage. Solvent exchange was 
performed in dialysis tubes from Spectrum Labs (Spectrum Laboratories, cellulose ester, MWCO 
500-1000 Da, 3.2 cm/mL, wet in 0.05% sodium azide) using water from a Milli-Q
®
 Direct 8 
water purification system (Merck Millipore). 
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Peptide synthesis and purification. All peptides were synthesized by solid phase peptide 
synthesis using a Syro I peptide synthesizer (MultiSyn Tech GmbH, Witten, Germany). AcX3gT 
was synthesized under the same conditions as previously published.
40
 The syntheses of the new 
H3gT and H3SSgT peptides were performed at a 0.17 mmol scale on a rink amide resin (0.71 
mmol/g reactive group concentrations) using standard fluorenylmethoxycarbonyl (Fmoc) 
chemistry and HCTU coupling protocols. At the end of the synthesis, the peptidyl resin was 
isolated and washed alternating with DMF, methanol, and dichloromethane. Cleavage from the 
resin and removal of protective groups was performed for 2 h in 10 mL containing 85% 
trifluoroacetic acid (TFA), 2.5% triisopropylsilane, 2.5% ethanedithiol, 5% thioanisole and 5% 
H2O for H3SSgT peptide, and a mixture of 95% TFA, 2.5% tetraethylsilane (TES), and 2.5% 
water for H3gT peptide. The cleavage cocktail was filtered and the resin was washed 
additionally with 1 mL fresh cleavage cocktail. The filtrate was then precipitated in 40 mL cold 
diethylether (H3SSgT) or diisopropylether (H3gT) and then pelleted by centrifugation. The 
precipitated crude peptides were washed with cold diethylether or diisopropylether and dried. 
The peptides were solubilized with ACN and aqueous TFA (0.05 %, v/v) and lyophilized. 
Purification was carried out by HPLC (Shimadzu Prominence 20A, Japan) on a C18 reverse 
phase (RP) column (Merck Chromolith, RP-18e, 100 mm x 10 mm and 100 mm x 4.6 mm) with 
mobile phases of water and acetonitrile containing 0.1% TFA while monitoring at 280 nm 
(gradient: 20%-65% ACN over 10 min). The molecular mass was determined by liquid 
chromatography electron spray ionization mass spectrometry (LC-ESI-MS) using an LS 
instrument from Shimadzu, amaZon X MS from Bruker (Germany) with a water-acetonitrile 
gradient of 5% to 95% ACN over 10 min (detection at 280 nm). The mass was obtained in 
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positive mode and referenced to parabene. Lyophilized peptides were stored in the freezer at -
20°C. 
Peptide nanoparticle formation and characterization. To prepare peptide nanoparticles, 
peptides were dissolved in 50% ethanol to obtain 1 mg/mL stock solutions and filtered through 
0.2 µm hydrophilic syringe filters. Stock solutions were diluted to a concentration of 0.2 mg/mL 
using 50% ethanol and subsequently dialyzed for approximately 16 h against water in prewashed 
500-1000 MWCO dialysis tubes, renewing the exchange solvent twice. After removal of the 
samples from dialysis tubing, the size distribution was measured from diluted samples in water 
(1:10 v:v) by dynamic light scattering (DLS). DLS and zeta-potential data were carried out using 
a Zeta Sizer Nano ZSP (Malvern Instruments Ltd., UK) at a fixed angle of θ = 173
o
 with a laser 
beam wavelength of 633 nm at room temperature. Transmission electron microscope (TEM) 
imaging was performed on a Philips CM100 TEM operating at an acceleration voltage of 80 kV. 
Samples were incubated for 2 min on hydrophilized, carbon coated, parlodion-(2% in n-butyl 
acetate) copper grids, and when necessary were negatively stained with a 2% uranyl acetate 
solution (10 s incubation). SEM micrographs were taken on a Philips XL 30 ESEM operating at 
5 kV. Samples were prepared on glass coverslips or mica and sputter-coated with silver or 
platinum. For Energy dispersive X-ray spectroscopy (EDX) analysis a FEI Nova NanoSEM was 
used operating at 10 kV. AFM profiles were obtained from a NanoWizard® III instrument from 
JPK Instruments AG using a PPP-NHCR cantilever (resonance frequency 204-497 kHz) and 
tapping mode in air. Confocal laser scanning micrographs (CLSM), fluorescence correlation 
spectroscopy (FCS) and fluorescence cross-correlation spectroscopy (FCCS) data were recorded 
on a commercial Confocor2 (Carl Zeiss, Jena, Germany), equipped with a laser diode (405 nm), 
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an Ar+ laser (514 nm), and two HeNe laser for 543 nm and 633 nm, using a 40x C-Apochromat 
water immersion objective with a numeric aperture of 1.2. 
Payload embedding. BODIPY 630/650 was diluted in dimethylsulfoxide (DMSO) to 1.5 mM, 
aliquoted and stored in the freezer at -20°C. 1 µL of 1.5 mM of bodipy was mixed with 100 µL 
peptide stock solutions (1 mg/mL), diluted to 500 µL with 50% ethanol and then dialyzed as 
described above. Atto550-AON-loaded peptide nanoparticles were prepared by addition of 4µL 
of 100 µM Atto550-AON solution to 100 µL peptide stock solutions (1 mg/mL) and diluted to 
500 µL with 35% ethanol. Then, the sample solution was dialyzed as described above. Co-
loading was performed by mixing 4 µL of 100 µM Atto550-AON with 1 µL of 1.5 mM 
BODIPY and 100 µL of 1 mg/mL peptide, further diluted to 500 µL with 35% ethanol and 
dialyzed. DoxHCl-peptide nanoparticles were prepared by adding 40 µL of a 10 mM DoxHCl 
solution in DMSO to 400 µL peptide stock solution, then diluted to 2 mL with 50% ethanol, 
mixed and dialyzed as described above. DoxHCl-peptide nanoparticles were separated from non-
embedded payload via three centrifugation/decantation cycles (29700 RCF at 5°C). Dox-loading 
was quantified by fluorescence (Perkin Elmer LS55 Luminescence Spectrometer, excitation 
wavelength: 490 nm, emission wavelength: 555 nm) using a standard dilution curve of DoxHCl. 
Loading of peptide nanoparticles with BODIPY, Atto550-AON was measured by fluorescence 
correlation spectroscopy (FCS). For BODIPY a HFT 633 / LP 650 filterset was used with a 
pinhole size of 90 µm and a 633 nm laser with a laser power of 5% while Atto550-AON was 
measured using a HFT 543 / LP 560 filterset with a pinhole size of 78 µm and a 543 nm laser at 
5% laser power. Loading was confirmed by confocal laser scanning microscopy (CLSM) for all 
three payloads: BODIPY, Atto550-AON and DoxHCl. For BODIPY a 633 nm laser at 10% 
transmission was used with NFT 545 and LP 650 filters with a pinhole of 92 µm, Atto550-AON 
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fluorescence was acquired using a 543 nm laser at 20% transmission and HFT 488/543 and LP 
560 filters with a pinhole of 78 µm. DoxHCl was detected using a 488 nm laser at 9.9% 
transmission with HFT 488, NFT 545, and LP 560 filters and a pinhole of 78 µm. 
Release Experiments. Release experiments were performed by mixing 45 µL of BODIPY- or 
AON-loaded peptide nanoparticles (0.2 mg/mL) with 5 µL of 100 mM dithiothreitol (DTT) 
dissolved in 100 mM HEPES buffer at pH 7.2 to obtain a 10 mM DTT solution (DTT is stable in 
Hepes during the experiments time scale). As control experiments, loaded peptide nanoparticles 
were diluted with 100 mM HEPES pH 7.2 to obtain 10 mM buffer concentration. Samples were 
stirred at room temperature and at indicated time points (2-120 min) 5 µL aliquots were 
withdrawn and measured subsequently 15 x 5 s by FCS (see payload embedding section for 
instrument settings). FCS data was fitted with a two-component model, where component 1 was 
fixed to a free payload diffusion (about 61 µs for BODIPY and about 102 µs for Atto550-AON) 
(without triplet state), the structural parameter was fixed to 5. All release experiments were 
performed in triplicate with error bars representing the standard error. TEM micrographs after 
DTT treatment were obtained using above described conditions. 
Characterization of BODIPY/AON co-loaded particles. Peptide nanoparticles were 
prepared as mentioned above. 5 µL of nanoparticles were placed on a glass slide and 
micrographs were acquired right above the surface. CLSM micrographs were obtained using a 
HFT UV/488/543/633, NFT 545, LP 650, and BP 530-600 filterset with 9.9% laser power and a 
pinhole of 82 µm for the 633 nm laser and 16% laser power and a pinhole of 76 µm for the 543 
nm laser. Images were processed and brightness profiles were obtained from the LSM image 
browser (Zeiss). FCCS data was recorded using HFT 514, LP 650, and BP 530-600 filters; a 514 
nm laser at 20% transmission with a pinhole of 70 µm and a 633 nm laser at 5% transmission 
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with a 70 µm pinhole. All data was fitted using a one-component model without triplet state and 
a structural parameter of 5 using ConfoCor3 software to obtain auto-correlation and the cross-
correlation functions: 
Gτfit = 1 + 1


	 1
1 + 

D
1
1 +  

D


 
τD is the diffusion time, N the number of particles, and R the structural parameter (was fixed to 
5). Relative cross-correlation amplitudes (RCA) were calculated using the cross-correlation 
amplitude Gx(0) and the auto correlation amplitudes of the Atto550-AON and BODIPY channel 
GAON,BODIPY(0), respectively: 
 = ,0 − 10 − 1  
The co-loading degree (CLD) was calculated by normalizing the data where the minimal cross-
correlation of a mixture of both payloads in solution was set to 0% and the maximal cross-
correlation from a double-labeled DNA standard (IBA standard) was set to 100%. 
Cell culture. HeLa cells were grown in Dulbecco’s modified eagle medium (DMEM) with 
10% fetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/mL streptomycin and 
maintained at 37 °C in 5% CO2. 
Cell viability assay. Cytotoxicity analysis was performed using the Promega CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation (MTS) assay to determine the number of viable 
cells in culture. Triplicate or pentaplicate wells containing 2000-5000 HeLa cells were seeded in 
a 96-well plate 24 h prior to the experiment in order to achieve confluency at the time of 
analysis. 10 µL of peptide nanoparticle solution were added to the cells to give final 
concentrations between 50-300 µg/mL or 25-1000 µg/mL and incubated for 24 h or 48 h at 37°C 
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with 5% CO2. MTS solution (20 µL/well) was added to the cells and then incubated for 2h. Cell 
viability in each well was calculated by measuring the absorbance of the cell solution (cells and 
media containing the nanoparticles) mixed with MTS solution at 490 nm using a SpectraMax 
M5
e
 (Molecular Device) spectrometer with a plate reader, and data was normalized against cells 
incubated with PBS (100% viability) and background subtracted with the absorbance from the 
MTS alone.  
Cellular uptake. HeLa cells (2x10
4
 cells per well) were seeded into an 8-well chamber 24 h 
prior to the experiment. After 24 hours, the cell culture media was replaced with Opti-MEM (130 
µL) followed by addition of 20 µL 0.2 mg/mL peptide nanoparticles. After 4 h incubation, the 
cell culture medium was replaced with serum-containing media (300 µL). The cells were then 
incubated for another 20 h. For cell uptake with serum the medium supplemented with 10% FBS 
was renewed prior to sample application. Prior to live cell imaging, the media was replaced by 
PBS and the cell nuclei were stained for 10 min with 1.6 µL of a 50 µg/mL Hoechst 33342 
solution in PBS. Cell imaging was performed by CLSM. The samples were excited at 405 nm 
(Hoechst 33342), 543 nm (for Atto550-AON), and 633 nm (for BODIPY) while collecting the 
emission after a BP 420-480 filter (Hoechst 33342), a BP 530-600 filter (Atto550-AON) and a 
LP 650 filter (BODIPY), respectively. Images were taken with the same acquisition settings for 
comparison purposes. 
Flow cytometry analysis. HeLa cells (7x10
4
 cells/well) were plated into 24-well tissue culture 
plates 24 hours prior to the experiment. The cell culture media was replaced with serum-free 
media (460 µL) and 40 µl 0.2 mg/mL peptide nanoparticles were added. After 4 h incubation, the 
serum-free medium was carefully removed and replaced with 1 ml of medium containing 10% 
FBS. The cells were then incubated another 20 h. Cells were trypsinized with 200 µl of trypsin 
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for 10 minutes at 37 °C and 5% CO2. Following trypsinization, 800 µl PBS were added to the 
cells, gently mixed by pipetting and transferred into 1.5 mL microcentrifuge tubes. Cells were 
then pelleted by centrifugation at 200 RCF for five minutes. Subsequently, the media was 
aspirated and the pellet was re-suspended in 250 µl PBS and put on ice. 6 µL of 50 µg/mL stock 
solution of Hoechst 33342 were added to each sample. Immediately prior to FACS analysis, the 
cells were vortexed gently. FACS measurements of BODIPY-loaded nanoparticles were 
performed by measuring at least 30000 cells with a FACS Canto II (BD, USA), the cells were 
excited with lasers at 405 nm and 633 nm, and the emitted light passed through a Band Pass 
450/40 and 660/20 filters, respectively, before reaching the detector. FACS measurements of 
Atto550-AON-loaded nanoparticles were performed by measuring at least 30000 cells with a BD 
LSR Fortessa, the cells were excited with lasers at 405 nm, 488 nm and 561 nm, the emitted light 
passed through Band Pass 450/50, 542/27 and 586/15 filters, respectively. The data were 
processed with FlowJo Vx (Tree Star, USA) and a fluorescence histogram of viable cells only 
was plotted or the mean fluorescence intensity was extracted. 
 
RESULTS AND DISCUSSION 
Design, synthesis, and characterization of peptides and their self-assemblies 
Two new amphiphilic peptides, H3gT and H3SSgT, were designed from the previously 
reported peptide, AcX3gT (Figure 2A). The first, H3gT, was designed with the cationic histidine 
amino acids in place of the acetylated lysines in order to improve the encapsulation of charged 
species such as AONs into the self-assembled nanoparticles (Figure 2B). In order to improve the 
release of cargo molecules from H3gT nanoparticles, a second peptide H3SSgT was designed by 
incorporating an artificial disulfide amino acid to serve as a reduction cleavable linker (Figure 
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2C). Inserting the linker between the hydrophilic oligo histidine and hydrophobic gT will lead to 
separation of the charged interactions of the oligo histidine and the hydrophobic interaction by 
the gT, leading to dissolution of the nanoparticle and release of the encapsulated molecules. The 
amphiphilic peptides AcX3gT, H3gT, and H3SSgT were synthesized using conventional solid 
phase peptide synthesis (SPPS) and purified by high-performance liquid chromatography 
(HPLC). The peptide masses of AcX3gT, H3gT, and H3SSgT were measured by liquid 
chromatography mass spectrometry (LC-MS) to match the expected values of 1653.9 g/mol, 
1512.8 g/mol, and 1746.8 g/mol, respectively (Figure S1).  
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Figure 2. Synthesized peptide sequences of AcX3gT (A)
40
, H3gT (B), and H3SSgT (C). The 
hydrophobic gT sequence is orange, the hydrophilic sequence is green, and the reducible S-S 
linker is blue. TEM micrographs represent self-assembled structures of each peptide. Scale bar: 
200 nm. 
Similar to AcX3gT, both H3gT and H3SSgT self-assembled in water leading to spherical 
nanoparticles. The change in the sequence from acetylated lysines of AcX3gT to oligo histidine 
of H3gT or H3SSgT did not affect the assembly properties of the amphiphilic peptides, revealing 
spherical shapes and a smooth surface by transmission electron microscopy (TEM) (Figure 2). 
However, the initial concentration of each peptide led to differences in nanoparticle size. For 
AcX3gT, there is a linear relation between initial concentration and nanoparticle size, with a 
lower plateau at 260 nm for concentrations below 0.5 mg/mL.
35
 In contrast, H3gT and H3SSgT 
exhibited sizes of about 200 nm for nanoparticles assembled from peptide concentrations of 0.2 
mg/mL. This is regarded as optimal size for drug delivery systems to have sufficient loading and 
good cell uptake
58
 but still avoid excessive clearance by macrophages
4, 59
. Replacing acetylated 
lysines of AcX3gT with histidines of H3gT did not alter the ability to form spherical 
nanoparticles in contrast to non-acetylated analogs of AcX3gT (K3gT).
35
 This can be attributed 
to a closer proximity between the side chain functional groups and its aromatic nature, which 
enables π-π-stacking, cation-π interactions and hydrogen-π interactions 
60
. 
 
Encapsulation of payload and characterization of loaded nanoparticles  
The ability of the new peptides H3gT and H3SSgT to embed payloads was compared to 
AcX3gT using a hydrophobic small drug molecule model (BODIPY), or an Atto550 labeled 
antisense oligonucleotide (AON). First, fluorescence correlation spectroscopy (FCS), which 
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distinguishes fluorescent species diffusing free in solution compared to those associated with 
nanoparticles, was measured to ensure the new peptides maintained the ability to load 
hydrophobic payloads. Varying the peptide sequence to include histidines or a reduction 
sensitive linker did not affect the incorporation of the hydrophobic molecule BODIPY (Table 1). 
AcX3gT and H3SSgT showed high loading efficiencies, however, upon encapsulating BODIPY 
in H3gT nanoparticles, the particles quickly shifted to large aggregates, which cannot be 
measured by FCS. The ratio of loaded cargo was obtained by fitting the autocorrelation functions 
using two component fits: free dye and dye-loaded peptide nanoparticles (Table 1). Next, AONs 
were loaded into each peptide nanoparticle. By FCS, AcX3gT showed a correlation curve 
identical to that of the free AON (Figure 3A). This indicated that AcX3gT was incapable of 
binding AONs due to a lack of charge interactions. However, both the H3gT and H3SSgT, which 
contain the oligo histidine sequence, were able to bind AONs showing an increased diffusion 
time compared to free AON alone (Figure 3A, Table 1). In contrast, the effective drug 
embedding efficiency of DoxHCl (as a hydrophilic small molecule drug) to H3gT and H3SSgT 
was determined to be 1.5 mg/g and 2.3 mg/g by fluorescence emission. The low embedding 
efficiencies resulted due to the hydrophilicity of DoxHCl, thus lacking entropic driving forces in 
contrast to hydrophobic payloads. Due to the inability of AcX3gT to bind AONs and the 
formation of large nanoparticles when H3gT encapsulates BODIPY, we will further focus on 
H3SSgT with the other two peptides being analyzed for comparison when appropriate. 
 
Table 1. FCS characterization of singly and co-loaded peptide nanoparticles. Data represents 
average ± SD (n=3). *Two components model fit of the autocorrelation function. 
Peptide Payload Diffusion Hydrodynamic  Loading 
efficiency* 
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Nanoparticles Time 
(µs) 
Diameter (nm) (%) 
Free species 
BODIPY 61.0 ± 2.8 N/A N/A 
AON 102.0 ± 7.3 N/A N/A 
AcX3gT 
BODIPY 7700 ± 440 174 ± 10 82 ± 7 
AON N/A N/A N/A 
H3gT 
BODIPY N/A N/A N/A 
AON 8430 ± 2400 235 ± 67 89 ± 3 
H3SSgT 
BODIPY 4550 ± 330 103 ± 8 93 ± 6 
AON 5640 ± 390 157 ± 11 99 ± 1 
Co-loaded 
H3SSgT 
BODIPY 4270 ± 760 96 ± 17 91 ± 2 
AON 3230 ± 640 90 ± 18 90 ± 3 
 
The successful incorporation of BODIPY and AONs into H3SSgT nanoparticles was 
confirmed by confocal laser scanning microscope (CLSM) (Figure 3F-G). Even the low DoxHCl 
loading was approved by CLSM micrographs (Figure 3H). The size and morphology of the 
nanoparticles were measured by dynamic light scattering (DLS) and scanning electron 
microscopy (SEM), respectively (Figure 3 B, C-E) and was confirmed by atom force microscopy 
(AFM) for DoxHCl-loaded H3SSgT particles (Figure S2). For AON- and DoxHCl-loaded 
particles only marginal differences in size and morphology were detected revealing smooth 
surfaces by SEM and diameters of 135 ± 22 nm and 165 ± 40 nm, respectively. In DLS the 
diameters have been obtained with the same order of magnitude (148 nm and 187 nm, 
respectively; Figure 3, Table S1), the differences being related to drying effect in SEM 
measurements. Particles loaded with BODIPY preserved the size as AON-loaded nanoparticles 
(149 nm; Figure 3, Table S1), but smaller diameters and rougher surfaces were observed by SEM 
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compared to non-loaded H3SSgT nanoparticles (Figure S3, Table S1). The difference in 
morphology of BODIPY-loaded particles can be attributed to hydrophobic interactions of 
BODIPY with the hydrophobic gT sequence of the peptide and the formation of intermolecular 
π-π-stacking between BODIPY and tryptophan
61
 interfering with the self-assembly process. The 
smaller sizes for AON-loaded compared to non-loaded particles can be attributed to the charge 
interaction resulting in more compact assemblies. Further analysis of the AON loaded 
nanoparticles was also performed using energy dispersive X-ray spectroscopy (EDX) to identify 
the simultaneous presence of the sulfur in the linker and the phosphorus of the AON backbone. 
Indeed, both elements were detected in AON loaded nanoparticles while no phosphorus signal 
was observed for particles loaded with BODIPY (Figure S4). Also, zeta-potential analysis 
showed an optimal DNA to peptide ratio at 40 µg AON/mg peptide where the surface charge 
approached from cationic, known to promote cell uptake
62
, towards neutral, known to decrease 
protein interactions and clearance (Figure S4).
63
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Figure 3. FCS autocorrelation curves (A) comparing free AON (dots) and AON complexed with 
AcX3gT (solid line), H3gT (broken line), and H3SSgT (dashes) nanoparticles. DLS data (B) for 
H3SSgT particles loaded with BODIPY (red), AON (green), and DoxHCl (blue). SEM and 
CLSM micrographs of H3SSgT nanoparticles loaded with BODIPY (C/F), AON (D/G), and 
DoxHCl (E/H). Scale bars for SEM micrographs are 200 nm (C-E), and 10 µm for CLSM 
micrographs (F-H).  
 
Stimuli-responsive disintegration of peptidic nanoparticles and release of payload 
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The implementation of a disulfide linker should allow H3SSgT nanoparticles to efficiently 
release loaded cargo molecules when exposed to physiological concentrations (10 mM) of 
dithiothreitol (DTT) through reductive cleavage of the hydrophilic from the hydrophobic 
sequence. Liquid chromatography mass spectrometry (LC-MS) was used to detect the 
decomposition of H3SSgT peptide before and after addition of reducing agent, corresponding to 
the full length peptide ([M+2]
2+
: 874.3; [M+3]
3+
: 583.2) (Figure S1 C) and the cleaved 
hydrophobic S-gT ([M+1]
+
: 1260.7 m/z; [M+2]
2+
: 630.8 m/z) (Figure S1 D). The detection of the 
H3-S sequence was not found due to it having a drastically lower molar absorption at 280 nm 
compared to the tryptophans on the gT sequence and it being hidden in the baseline. Next, 
H3SSgT nanoparticles were investigated using TEM and SEM to visualize if the cleavage of the 
peptide led to subsequent destruction of the nanoparticles. After addition of DTT the 
micrographs showed decomposition of the spherical nanoparticles compared to H3SSgT 
nanoparticles without DTT (Figure 4). The smaller particles represent partly decomposed peptide 
nanoparticles due to the disintegration of the particles. The population with larger diameters 
suggests the aggregation of the cleaved hydrophobic gT sequence due to their instability in 
aqueous solution (Figure 4B). TEM micrographs and DLS indicate the coexistence of various 
stages of particle decomposition after DTT addition, ranging from intact peptide nanoparticles up 
to aggregates (Figure S5). AcX3gT and H3gT did not show particles decomposition when treated 
with DTT (Figure S6). 
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Figure 4. TEM (top) and SEM (bottom) micrographs of responsive H3SSgT nanoparticles 
before (A) and after treatment with DTT (B). Scale bars: 200 nm. 
 
FCS was then used to assess the simultaneous release of payload during particle 
decomposition. We selected BODIPY to be co-delivered with AON because it is appropriate as 
model molecule in terms of hydrophobicity and molecular weight, being in addition a fluorescent 
molecule easy to be detected by FCS. Due to the incompatibility of DoxHCl with FCS detection, 
it was not feasible to use this small molecule drug for these release assays. 10 mM DTT was 
added to H3SSgT nanoparticles loaded with BODIPY or AON. Nanoparticles loaded with AON 
showed a fast release profile reaching approximately 50% after 15 minutes, while with BODIPY 
50% release was not achieved until 30 min (Figure 5). Fast release under reductive conditions 
while maintaining payloads, when incubated in buffer differentiate our system from slowly 
releasing, pH-sensitive peptide nanoparticles showing a pH 5/pH 7.4-release ratio of 2.
42
 
Similarly, our system is faster than amphiphilic peptides passively releasing hydrophobic 
payload from gene/drug co-loaded particles to 35% after 18 h,
49
 or 40% after 60 h.
50
 Both 
BODIPY- and AON-nanoparticles showed almost complete disintegration by 120 minutes in the 
presence of DTT, with no release occurring without DTT (Figure 5). The slightly higher release 
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rate of AONs can be associated to their hydrophilicity, positioning them on the outer hydrophilic 
corona of the individual micelles, whereas the hydrophobic payload is trapped in the micelles 
core, shielded by the hydrophilic part of the peptide. The release from H3SSgT in the presence of 
DTT was then compared with AcX3gT, for BODIPY loaded nanoparticles, or H3gT, for AON 
loaded nanoparticles. AcX3gT and H3gT, treated with DTT, did not result in an increased 
population of freely diffusing payload indicating no release (Figure 5).  
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Figure 5. Release curves of BODIPY (A) or AON (B) loaded nanoparticles: squares represent 
H3SSgT+DTT, circles are H3SSgT-DTT, triangles are AcX3gT+DTT, and diamonds represent 
H3gT+DTT. Green and red lines are exponential fits of the H3SSgT data points using the 
Levenberg Marquardt algorithm. Data represents average ± SD (n=3). 
 
Co-loading and combined release from H3SSgT nanoparticles 
To assess the suitability of the stimuli-responsive H3SSgT nanoparticles to serve as 
multifunctional co-delivery carriers they were co-loaded with both AONs and BODIPY. The co-
loaded peptide nanoparticles were analyzed with CLSM to evaluate the simultaneous existence 
of both payloads in the particles (Figure 6A-C). An intensity profile through the micrograph 
indicated that not all particles are loaded equally (Figure 6D), but that most of the particles 
contained both AON and BODIPY. Fluorescence cross-correlation spectroscopy (FCCS) was 
used to quantify the fraction of co-loaded nanoparticles. FCCS is a dual-color variant of the FCS 
technique for the co-localization of two different fluorophores by cross-correlation of the 
individual channels
64
. All data were normalized with the free cargo mixture equaling 0% cross-
correlation and a standard double labeled DNA equaling 100% cross-correlation. It resulted in a 
calculated complete co-loading of the particles (Figure S7). To evaluate if the responsiveness 
was influenced by co-loading, co-release of both BODIPY and AON was compared by FCS to 
singly loaded nanoparticles. 50% of BODIPY was released faster from co-loaded nanoparticles 
at around 10 min (Figure 6E) compared to singly loaded ones (≈ 30 min) (Figure 5A). This could 
be attributed to the additional interaction of both cargoes with the peptide, affecting the 
hydrophilic and hydrophobic interactions and potentially disturbing the assembly leading to less 
density within the nanoparticles, in contrast to peptide nanoparticles bearing only one type of 
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guest molecules (Figure 5). The AON release behavior is almost congruent with singly loaded 
analogs due to different binding mode to the carrier.  
 
Figure 6. CLSM micrographs of AON (A, red channel) and BODIPY (B, green channel) co-
loaded H3SSgT nanoparticles (C, merged). Fluorescence intensity profile of a cross section of 
micrograph C (D). FCS release curve of BODIPY and AONs from co-loaded H3SSgT 
nanoparticles with DTT (E). Data represents average ± SD (n=3). 
 
Cell uptake and anti-proliferation activity 
The reduction sensitive H3SSgT nanoparticles were evaluated for cytotoxicity to ensure the 
particles do not rapidly cause cell death. Peptide nanoparticles were non-toxic for concentration 
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up to 1000 µg/mL at incubation times of 24 h and 48 h (Figure S8-A). Also, when the 
nanoparticles were treated with DTT prior to viability experiments the fragments did not show 
any toxicity after 48 h incubation (Figure S8-C). Cell toxicity for the free peptides could not be 
achieved due to the spontaneous self-assembly in aqueous media. Cell uptake and intra cellular 
behavior in HeLa cells were investigated with H3SSgT nanoparticles loaded with BODIPY or 
AON or co-loaded with both BODIPY and AON. Qualitative analysis of the cells by CLSM 
showed increased uptake for singly loaded (Figure S9 and S10) and co-loaded peptide 
nanoparticles with BODIPY (Figure 7A) and AON (Figure 7C). Cellular uptake was additionally 
demonstrated to be comparable for co-loaded particles when initially incubated in serum-
containing medium (Figure S12). The increased uptake to cells was subsequently quantified by 
fluorescence-assisted cell sorting (FACS) analysis. This resulted in a 10-fold higher uptake of 
embedded AONs compared to free AONs when equivalent AON concentrations were applied to 
the cells (Figure 7E). Free cargo as well as a mixture of BODIPY and AON (to ensure no cross 
interaction of molecules leading to uptake) did not show any detectable uptake (Figure S9-S11). 
This was expected for the negatively charged AON because it is commonly known that large 
anionic molecules do not internalize into cells. Free BODIPY is often shown to enter the cell, 
however, the amount of free BODIPY was the same as that in the particle solutions. At such low 
concentrations, free BODIPY was not enough to be seen by CLSM whereas when co-localized 
into peptide nanoparticles and more readily uptaken due to the positive surface charge, higher 
signals have been observed.  
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Figure 7. CLSM micrographs of co-loaded H3SSgT peptide nanoparticle accumulation in HeLa 
cells with BODIPY channel (A), Hoechst nucleus stain (B), AON channel (C), and merged (D). 
FACS data of cell uptake for AON loaded particles obtained from mean fluorescence intensities 
(E). Cell growth inhibition studies of free DoxHCl, or DoxHCl loaded H3gT and H3SSgT 
peptide nanoparticles (F).  
For subsequent cell growth inhibition studies only the H3gT and H3SSgT particles were 
loaded with hydrophilic DoxHCl to demonstrate the cell uptake and delivery qualities as well as 
the protection of the drug for more effectiveness. To assess the applicability of stimuli-
responsive peptide nanoparticles as drug delivery system, DoxHCl was loaded into H3SSgT 
nanoparticles and applied to HeLa cells. The IC50 value of DoxHCl-loaded peptide 
nanoparticles was determined for H3SSgT compared to free Dox (Figure 7F). The IC50 of 
DoxHCl loaded H3SSgT peptide nanoparticles (H3SSgT) was found to be 150 nM, 
approximately four-times lower than for free DoxHCl (530 nM). The decrease of IC50 is due to 
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the hydrophilic character of DoxHCl, which has limited cell permeability compared to the 
nanoparticles. The decrease of IC50 value compared to free DoxHCl in HeLa cells is an indirect 
proof of DoxHCl release from nanoparticles upon uptake, and supports our system as a good 
candidate for co-delivery of small molecular weight molecules and AON. In addition, as the 
peptide fragments did not show any toxicity after 48 h incubation (Figure S8-C), we consider 
that the lower IC50 of DoxHCl loaded H3SSgT nanoparticles than DoxHCl loaded H3gT 
nanoparticles is the results of better DoxHCl release from H3SSgT nanoparticles due to the S-S 
breakage. 
Also, when compared to the non-reducible DoxHCl loaded H3gT nanoparticles (280 nM), 
H3SSgT had an IC50 about two times lower. This difference demonstrates the influence of the 
added stimuli-responsive linker. H3gT nanoparticles are taken up by cells similarly to H3SSgT 
but do not rapidly or efficiently release the DoxHCl, which is why the IC50 remains higher. The 
stimuli-responsive H3SSgT particles reveal, in addition to a similar uptake performance 
compared to H3gT, a potent release mechanism allowing the drug to achieve its full potential. 
Endosomal escaping capacity of the nanoparticles will be evaluated in further experiments in 
conjunction with other more biologically relevant studies. 
 
CONCLUSION 
Development of non-toxic, biocompatible, and biodegradable nanocarriers for co-delivery and 
stimuli-responsive release of oligonucleotides and small drugs remains a remarkable challenge. 
We designed and synthesized responsive amphiphilic peptides, which assemble into peptide 
nanoparticles that were engineered to condense oligonucleotides via electrostatic interactions 
with histidine and to incorporate small molecules within their multicompartment micellar 
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structure. The nanoparticles are able to carry hydrophobic and hydrophilic payloads as well as 
oligonucleotides, which can be released upon a physiological trigger. In addition, the histidines 
in the primary sequence support uptake to cells and subsequent proton sponge effect accelerating 
endosomal escape by its buffering capacity. Unlike most reported co-delivery systems, our 
stimuli-responsive nanoparticles are purely peptidic in nature and therefore intrinsically 
biodegradable. In contrast to the earlier reported peptidic co-delivery system based on Fmoc-
lysine-histidine constructs revealing sizes of up to 550 nm,
42
 the diameter of the present 
nanoparticles match desired values for intravenous application. Furthermore, the implemented 
release mechanism is highly sensitive to a reduction potential in the cytosol to release co-loaded 
payloads with great efficiency. All of these characteristics make our peptide nanoparticles a 
promising candidate for co-delivery of multiple therapeutic payloads including hydrophobic Dox 
and plasmid DNA. Therefore, ongoing optimization experiments exploring the biocompatibility 
of these nanoparticles, their stability in animal blood serum and in vivo biodistribution and 
pharmacokinetic studies are planned to improve this system into a functional delivery system 
with high therapeutic effects.  
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